Highest-materiality recent filing
Grace Therapeutics updates corporate presentation; no specific details available in filing
Filed updated corporate presentation as Exhibit 99.1 dated June 17, 2026.
Grace Therapeutics FY2026 net loss $7.8M; FDA CRL for GTx-104; Type A meeting set
Net loss of $7.8M ($0.47 loss per share) for FY2026, improved from $9.6M loss in FY2025.
Grace Therapeutics VP of Clinical Ops departing, will consult at $250/hr for NDA work
Carrie D'Andrea, VP of Clinical Operations, to cease employment effective June 5, 2026.
Grace Therapeutics updates corporate presentation in routine 8-K
Filed an updated corporate presentation as Exhibit 99.1 on April 27, 2026.
FDA CRL for GTx-104 (nimodipine IV) in aSAH; no additional clinical data requested.
Net loss of $2.3M ($0.14 per share) improved from $4.2M loss ($0.36 per share) in prior year quarter.
Grace Therapeutics amends severance for CEO (12-18 mo) and 4 execs (6 mo) as of Jan 10, 2026
CEO Prashant Kohli gets 12 mo base salary (no CIC) or 18 mo base+target bonus (CIC) plus COBRA.
Grace Therapeutics reports Q2 loss of $0.9M; FDA accepts NDA for GTx-104 with PDUFA April 23, 2026
Net loss $0.9M ($0.06 loss per share) vs $3.4M ($0.30 loss) in Q2 last year.
Grace Therapeutics secures $4.0M from warrant exercise; GTx-104 PDUFA date set for April 23, 2026
Secured $4.0M via exercise of 1,345,464 common warrants at $3.003/share from September 2023 private placement.
US Patent 12,414,943 issued for I.V. nimodipine dosing regimen used in Phase 3 STRIVE-ON trial.
Five director nominees elected: Vimal Kavuru, A. Brian Davis, Prashant Kohli, S. George Kottayil, Edward Neugeboren; votes for ranged 6.29M-6.30M.
FDA accepts Grace Therapeutics' NDA for GTx-104; PDUFA date set for April 23, 2026
FDA accepted NDA for GTx-104 (injectable nimodipine) for aSAH treatment; PDUFA target April 23, 2026.
Grace Therapeutics reports Q1 net loss $3.4M; submits GTx-104 NDA to FDA
Net loss $3.4M ($0.21/sh) vs $2.6M ($0.24/sh) in prior-year quarter; R&D down $1.8M to $0.9M.
Grace Therapeutics submits NDA for GTx-104 in aSAH; Phase 3 data positive
NDA for GTx-104 (injectable nimodipine) submitted to FDA for aneurysmal subarachnoid hemorrhage.
Net loss of $9.6M ($0.79 per share) vs $12.9M ($1.35) in FY2024, decrease driven by change in warrant liabilities.
Primary endpoint met: 19% reduction in clinically significant hypotension (28% GTx-104 vs 35% oral nimodipine).
Grace Therapeutics updates corporate presentation with cash and runway guidance
Corporate presentation updated as of March 3, 2025; includes cash position and runway guidance.
Grace Therapeutics Q3 net loss $4.2M; Phase 3 STRIVE-ON meets endpoint; $15M placement
Net loss $4.2M ($0.36/sh) vs $2.4M ($0.21/sh) YoY; R&D $2.2M up from $1.4M on GTx-104 trial.
Grace Therapeutics: Phase 3 STRIVE-ON trial meets endpoint; announces up to $30M private placement
Phase 3 STRIVE-ON safety trial met primary endpoint: 19% reduction in clinically significant hypotension vs oral nimodipine; NDA submission expected H1 2025.
Grace Therapeutics reports Q2 net loss $3.4M; Phase 3 STRIVE-ON data due Q1 2025; cash into Q2 2026
Net loss of $3.4M ($0.30 per share) vs $3.3M ($0.43 per share) in prior year; R&D spend up to $3.0M on pivotal trial.
Acasti Pharma changes name to Grace Therapeutics; Nasdaq ticker becomes GRCE
Name changed from Acasti Pharma Inc. to Grace Therapeutics, Inc., effective Oct 28, 2024.
Acasti Pharma rebrands as Grace Therapeutics; new ticker GRCE effective Oct 28
Company renamed Grace Therapeutics, Inc.; common stock begins trading as GRCE on Nasdaq at market open Oct 28, 2024.
Acasti Pharma redomiciles from Canada to Delaware effective October 7, 2024
Changed jurisdiction from Quebec to British Columbia (Oct 1) and then to Delaware (Oct 7, 2024).
Shareholders approved continuance from Quebec to British Columbia (5,874,491 For, 71,931 Against, 8,683 Abstain).
Acasti Pharma completes enrollment in pivotal Phase 3 STRIVE-ON trial of GTX-104 for aSAH
Patient enrollment completed for GTX-104 (injectable nimodipine) vs oral nimodipine in 100 patients across ~25 U.S. hospitals.
Acasti Pharma enters new employment agreement with CEO Prashant Kohli
Annual base salary of $500,000 and eligible for discretionary bonus up to 50% of base.
Acasti Pharma Q1 FY2025 net loss $2.6M; STRIVE-ON trial enrollment exceeds 50%
Net loss of $2.6M ($0.24 loss per share) vs $4.0M ($0.54) in prior-year quarter.
Acasti achieves >50% enrollment in pivotal Phase 3 STRIVE-ON safety trial for GTX-104
Phase 3 STRIVE-ON trial of GTX-104 (IV nimodipine) for aneurysmal subarachnoid hemorrhage (aSAH) surpassed 50% patient enrollment.
Acasti Pharma FY2024 net loss $12.9M; STRIVE-ON trial on track for NDA in H1 2025
FY2024 net loss $12.9M ($1.35 per share), down from $42.4M in FY2023; decrease due to prior year impairments not recurring and restructuring.
Acasti Pharma updates corporate presentation; no material new information disclosed
Updated corporate presentation dated April 1, 2024, furnished as Exhibit 99.1.
Acasti Pharma Q3 FY2024 net loss narrows to $2.4M; cash runway extends to early 2026
Net loss of $2.4M ($0.21/share) vs $3.9M ($0.52) in prior-year quarter.
Robert J. DelAversano, 52, CPA and former VP Finance, becomes principal financial and accounting officer.
Acasti Pharma dismisses Ernst & Young, engages KPMG as new auditor
Board approved dismissal of E&Y as independent auditor on Dec 11, 2023; E&Y letter filed as Exhibit 16.1.
Acasti Q2 FY2024 net loss falls to $3.3M; first patient dosed in pivotal GTX-104 trial
Net loss of $3.3M ($0.43/share) vs $5.0M ($0.66/share) in Q2 FY2023; R&D spending cut to $0.4M.
Acasti Pharma Settles CaPre Dispute with Aker BioMarine and Doses First Patient in GTX-104 Trial
Acasti entered a Settlement Agreement with Aker BioMarine to resolve a $2.6 million dispute over a supply agreement for CaPre raw material.
Acasti Pharma shareholders elect directors, ratify auditor, approve exec comp at annual meeting
Five director nominees elected with >97% votes for each; non-votes ~1.27M.
Acasti Pharma closes $7.5M private placement for GTX-104 development
Closed private placement on Sept 25, 2023: 1.95M common shares at $1.848 each, pre-funded warrants for 2.11M shares, and common warrants for 2.54M shares at $3.003 exercise.
Acasti Pharma Q1 net loss $4.0M; FDA aligned on Phase 3 GTX-104 trial; cash runway to Q2 2025
Net loss $4.0M ($0.54 per share) vs $4.5M ($0.61 per share) year ago.
Acasti Pharma regains Nasdaq minimum bid price compliance after reverse split
Received Nasdaq notice on July 24, 2023 confirming compliance with Listing Rule 5550(a)(2).
Acasti Pharma announces 1-for-6 reverse stock split to regain Nasdaq minimum bid price compliance
Reverse split at 1-for-6 effective July 10, 2023; shares trade on split-adjusted basis from market open.
Acasti aligns with FDA on GTX-104 Phase 3 safety trial protocol; STRIVE-ON to start Q4 2023
FDA confirmed alignment on STRIVE-ON trial design and dosing regimen for GTX-104 in aSAH patients.
Acasti Pharma reports FY2023 net loss of $42.4M, focuses on GTX-104 Phase 3
Net loss of $42.4M ($0.95 loss per share) vs $9.8M loss prior year; impairments of $33.5M.
Appointed Dr. R. Loch Macdonald as CMO, Carrie D'Andrea as VP Clinical Ops, Amresh Kumar as VP Program Mgmt; effective immediately or May 15.
Acasti appoints Prashant Kohli as CEO; FDA allows Phase 3 safety study for GTX-104 to proceed
Prashant Kohli appointed CEO effective April 4, 2023, succeeding Jan D'Alvise who mutually agreed to depart.
Director John Canan resigns from Acasti Pharma board, no dispute
Jean-Marie (John) Canan resigned from the board effective March 30, 2023.
Acasti voluntarily delists from TSX Venture; confirms no SVB/Silvergate exposure
Voluntary delisting from TSXV effective March 27, 2023; Nasdaq listing under ACST unaffected.
Carrie D’Andrea will cease serving as Vice President of Clinical Operations of the Company and will no longer be employed by the Company effective June 5, 2026
Concurrently with such appointment, the Board removed Brian Ford from the position of interim-Chief Financial Officer.
On January 5, 2024, the Board of Directors (the “Board”) of Acasti Pharma Inc. (the “Company”) approved the appointment of Robert J. DelAversano, the Company's Vice President, Finance, to the roles of principal financial officer and principal accounting officer of the Company, effective immediately.
On May 8, 2023, the Company terminated the employment of Brian Ford, Chief Financial Officer; Pierre Lemieux, Chief Operating Officer (Canada); and George Kottayil, Chief Operating Officer (US).
On May 8, 2023, the Company appointed Amresh Kumar, PhD, as its VP of Program Management, effective May 15, 2023.
On May 8, 2023, the Company terminated the employment of Brian Ford, Chief Financial Officer; Pierre Lemieux, Chief Operating Officer (Canada); and George Kottayil, Chief Operating Officer (US).
On May 8, 2023, the Company appointed Dr. R. Loch Macdonald, MD, PhD, as Chief Medical Officer, effective immediately.
On May 8, 2023, the Company terminated the employment of Brian Ford, Chief Financial Officer; Pierre Lemieux, Chief Operating Officer (Canada); and George Kottayil, Chief Operating Officer (US).
On May 8, 2023, the Company appointed Carrie D'Andrea as its VP Clinical Operations, effective immediately.
Ms. D'Alvise will also be stepping down from the Company's board of directors.
succeeding Jan D'Alvise, who has mutually agreed with the Company to depart.
On April 4, 2023, Acasti Pharma Inc. (the "Company") announced it has appointed Prashant Kohli as the Company's Chief Executive Officer, succeeding Jan D'Alvise, who has mutually agreed with the Company to depart.
Max materiality 0.85 · Median 0.62 · Most common event other_material